Accredited Online Training Programs
Many of the BioPharma Institute’s professional clinical research, regulatory affairs, and drug safety training programs are are accredited, and offer Continuing Professional Development (CPD) points by the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom.
On completion of each course, learners earn CPD points in proportion to the course’s duration. The CPD points earned are specified on the certificate awarded to the learner on successful completion of the course’s multiple-choice-question assessment.
Below you will find a list of the courses which offer these CPD point upon completion.
CPD points for Accredited Training Courses
|
BP ID |
CPD ID |
Title |
CPD points |
|
GCP020 |
CT01 |
How to Gain Approval to Conduct Clinical Trials in |
3 |
|
GCP001 |
CT03 |
An Introduction to ICH Good Clinical Practice |
3 |
|
GCP002 |
CT04 |
An Introduction to Clinical Trial Preparation and Design |
4 |
|
GCP004 |
CT06 |
Clinical Trial Monitoring: Site Evaluation and Set-up |
1.5 |
|
GCP003 |
CT07 |
An Introduction to Clinical Trials and Drug Development |
1.5 |
|
GCP005 |
CT08 |
Clinical Trial Monitoring: Study Monitoring, Documentation |
2 |
|
GCP006 |
CT09 |
Good Clinical Practice Inspections and Audits |
2.5 |
|
GCP007 |
CT10 |
The Investigational New Drug Application (IND) to Conduct |
3 |
|
PRA01 |
ESS01 |
Essentials of EU and US Regulatory Affairs for Human |
3 |
|
DS001 |
PV03 |
An Introduction to Drug Safety and Pharmacovigilance |
2 |
|
NA |
QAC01 |
An Introduction to Good Quality Control Laboratory |
2 |
|
NA |
SC01 |
Pharmacokinetics and Pharmacodynamics in Drug Registration |
3.5 |
|
PRA02 |
SUB01 |
Orphan Drug Designation in the USA and Europe |
1.5 |
|
PRA20 |
SUB02 |
The European Centralised Procedure (CP) |
1.5 |
|
PRA21 |
SUB03 |
The Mutual Recognition Procedure (MRP) |
2 |
|
PRA03 |
SUB04 |
Preparing Submissions in the Common Technical Document |
1.5 |
|
PRA04 |
SUB05 |
Electronic Common Technical Document (eCTD) |
2.5 |
|
PRA22 |
SUB06 |
Variations to Marketing Authorisations in Europe |
3.5 |
|
PRA005 |
SUB07 |
Registration of Monoclonal Antibodies |
3 |
|
PRA06 |
SUB08 |
How to Gain Approval to Market a Generic Medicinal |
3.5 |
|
PRA07 |
SUB09 |
The New Drug Application (NDA) for Marketing Approval |
3.5 |
|
PRA23 |
SUB11 |
The Decentralised Procedure (DCP) |
2 |
